Le Lézard
Classified in: Health
Subjects: SVY, BFA

A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd


STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac")  is published in the June edition of MedNous, through a written commentary by CEO Anders Månsson.

In order to further attract the attention of potential partners and increase their interest in RhoVac's achievements as well as plans for the future, RhoVac's CEO Anders Månsson has written a commentary on the company in the latest edition of MedNous that was published last week.  

CEO Anders Månsson comments: "It is important that we communicate on RhoVac more broadly than what can be accomplished in direct bi-lateral meetings, whether physical or digital. By reaching out also via the international press, informing on our achievements and our plans, we can also reach a broader audience and that is important from a business perspective."

Link to the commentary on RhoVac in MedNous:https://www.rhovac.com/investors/presentations/

For further information, please contact:

Anders Månsson 
CEO, RhoVac AB
Phone number: +46-73-751 72 78
E-mail: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/rhovac/r/a-rhovac-article-is-published-in-the-june-edition-of-mednous--a-publication-of-evernow-publishing-lt,c3146641

The following files are available for download:

https://mb.cision.com/Main/13747/3146641/1273063.pdf

Release

 

SOURCE RhoVac


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: